AzTrials
AzTrials

Breast CancerPhase 2NCT02389764

Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

A Phase 2 study testing BIBF 1120 and Phone Call in people with Breast Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The goal of this clinical research study is to learn if Ofev® (nintedanib, also called BIBF1120) can help to control IBC. The safety of this drug will also be studied. This is an investigational study. Nintedanib is commercially available and FDA approved for the treatment of certain types of lung disease. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Breast Cancer
What is being tested?
BIBF 1120 and Phone Call
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteUnited States
Study dates
22 Jun 2015to 8 Jun 2019
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients are 18 years of age or older
  • Patients are female or male.
  • Have histological confirmation of breast carcinoma with a clinical diagnosis of IBC based on presence of inflammatory changes in the involved breast, including diffuse erythema and edema (peau d'orange), with or without an underlying palpable mass involving the majority of the skin of the breast. Pathological evidence of dermal lymphatic invasion should be noted but is not required at diagnosis.
  • Have confirmed distant metastasis with or without local recurrence.
  • Have negative HER2 expression by IHC (defined as 0 or1+), or FISH. If HER2 is 2+, negative HER2 expression must be confirmed by FISH.
  • Patients may undergo an optional biopsy of the metastatic disease at baseline and after 2 cycles of BIBF-1120.
Show all 13Show fewer
  • Estimated life expectancy of at least 3 months
  • Have ECOG performance status score 0-2
  • Have received at least one any prior treatment for local recurrence or metastatic disease and have relapsed.
  • Signed and dated written informed consent prior to admission to the study
  • If Patients have been treated with anti-VEGF agents, such as Bevacizumab, last dose must be >/= 4 weeks.
  • Have tissues from a biopsy, or have up to 20 unstained slides available from archived metastatic tissue block for biomarker evaluation
  • Patients are able to swallow and retain oral medication

Who cannot join

  • Patients have an active infection and require IV or oral antibiotics.
  • Patients have impaired cardiac function or clinically significant cardiac diseases, including any of the following: a) History or presence of serious uncontrolled ventricular arrhythmias or presence of atrial fibrillation; b) Clinically significant resting bradycardia (< 50 beats per minute); c) LVEF assessed by 2-D echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) < 45%; d). pericardial effusion
  • Any of the following within 6 months prior to study entry: myocardial infarction (MI), severe/unstable angina, Coronary Artery Bypass Graft (CABG), Congestive Heart Failure (CHF) > NYHA II, Cerebrovascular Accident (CVA), Transient Ischemic Attack (TIA), Pulmonary Embolism (PE),
  • Uncontrolled hypertension defined by an SBP>150 and/or a DBP>100 mm Hg with or without anti-hypertensive medication
  • History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug as determined by the investigator.
  • Patients have a concurrent disease or condition that would make them inappropriate for study participation, or any serious medical disorder that would interfere with patients' safety as determined by the investigator.
Show all 32Show fewer
  • Patients with only locally or regionally confined disease without evidence of metastatic disease
  • Prior treatment with BIBF 1120 or any other VEGFR inhibitor within 4 weeks
  • Known hypersensitivity to the trial drugs , to their excipients or to contrast media
  • Chemotherapy, hormonal therapy, radiotherapy (except for brain and extremities) or immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks prior to treatment with the trial drug
  • Persistence of toxicity from previous chemo and/or radiotherapy > grade 2.
  • Active brain metastases (e.g. stable for <4 weeks, no adequate previous treatment with radiotherapy, symptomatic, requiring treatment with anti-convulsants; dexamethasone therapy will be allowed if administered as stable dose for at least one month before randomisation).
  • Radiographic evidence of cavitary or necrotic tumors
  • Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of major blood vessels
  • Treatment with other investigational drugs or treatment in another clinical trial within the past 4 weeks before start of therapy or concomitantly with the trial
  • Therapeutic anticoagulation( except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid < 325mg per day
  • Major injuries within the past 10 days prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period
  • History of clinically significant haemorrhagic or thromboembolic event in the past 6 months
  • Known inherited predisposition to bleeding or thrombosis
  • Proteinuria CTCAE grade 2 or greater
  • Creatinine >/= 1.5 x ULN or GFR < 45 ml/min
  • Hepatic function: total bilirubin outside of normal limits; ALT or AST >1.5 x ULN in pts without liver metastasis. For Pts with liver metastasis: total bilirubin outside of normal limits, ALT or AST >2.5 x ULN
  • Coagulation parameters: International normalised ratio ( INR) > 2, prothrombin time (PT) and partial thromboplastin time (PTT) > 50% of deviation of institutional ULN
  • Absolute neutrophil count ( ANC) < 1500/ml, platelets < 100000/ml, Haemoglobin < 9.0 g/dl
  • Other malignancies within the past 5 years other than basal cell skin cancer or carcinoma in situ of the cervix
  • Known history of active or chronic hepatitis C and/or B infection
  • Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study.
  • Patients who are sexually active and unwilling to use a medically acceptable method of contraception (e.g. such as implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner for participating females) during the trial and for at least three months after end of active therapy (Contraception in patients with preserved reproductive capacity, patients will be considered to be of childbearing potential unless surgically sterilised by hysterectomy or bilateral tubal ligation/salpingectomy, or post-menopausal for at least two years.)
  • Patients with child bearing potential must have a negative pregnancy test (urine or serum) prior to study treatment
  • Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule
  • Active alcohol or drug abuse
  • Significant weight loss (> 10% of BW) within past 6 months prior to inclusion into the trial

Trial locations and contacts

1 site in 1 country.

United States1 site

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030

Other trials in United States

About this study

Official title: A Phase II Study of BIBF1120 (Nintedanib) for Patients With Metastatic HER2-Negative Inflammatory Breast Cancer (IBC)

The goal of this clinical research study is to learn if Ofev® (nintedanib, also called BIBF1120) can help to control IBC. The safety of this drug will also be studied.

This is an investigational study. Nintedanib is commercially available and FDA approved for the treatment of certain types of lung disease. Its use in this study is investigational. The study doctor can explain how the study drug is designed to work.

Up to 44 participants will be enrolled in this study. All will take part at MD Anderson.

Read the detailed description

Study Drug Administration:

Each study cycle is 4 weeks.

If you are found to be eligible to take part in this study, you will take nintedanib capsules by mouth 2 times each day. Each dose should be about 12 hours apart, at about the same times every day. The capsules should be swallowed whole with about a cup (8 ounces) of water within 30 minutes after eating a meal.

If you forget to take the capsules and it has been more than 2 hours since you were scheduled to take the dose, you should skip that dose and take the next dose as scheduled. Do not double the next dose to "make up" the missed one.

You will be given a study drug diary to write down when you took each dose of study drug. You will need to bring back any empty or partially used bottles of study drug, along with any leftover study drug, with you to the clinic at each cycle.

If you experience side effects, you will be given standard drugs to help decrease the symptoms of the side effects. You may ask the study staff for information about how the drugs are given and their risks.

Study Visits:

All tests and procedures below will be performed before your dose of study drug.

On Day 1 of every cycle:

  • You will have a physical exam.
  • Blood (about 2 tablespoons) will be drawn for routine tests.

On Day 1 of Cycles 1-7 and then every odd-numbered cycle after that (Cycles 9,11, 13, and so on), the physical exam and blood draw will be performed at MD Anderson . On Day 1 of Cycles 8 and then every even-numbered cycle after that (Cycles 10, 12, 14, and so on), the physical exam and blood draw may be performed at a local clinic or doctor's office and the results will be sent to the study doctor for review. The study doctor will discuss this option with you.

On Day 1 of Cycle 3, blood (about 2 tablespoons) will also be drawn for biomarker testing.

On Day 1 of Cycles 3, 5, 7, and then every odd numbered cycle after that (Cycles 9, 11, 13, and so on):

  • If the doctor thinks it is needed, photographs will be taken of any areas affected by the disease.
  • If the doctor thinks it is needed, you will have an x-ray, ultrasound, CT scan, PET/CT scan, and/or a bone scan to check the status of the disease.

At any point that the doctor thinks it is needed, you will have an EKG, ECHO, and/or MUGA scan. You may have any of the above tests/procedures repeated as well, if the doctor thinks it is needed, to check on your health.

Length of Study:

You may continue taking the study drug for up to 2 years. You will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions.

Your participation on the study will be over after you have completed the follow-up period.

End-of-Treatment Visit:

Within 14 days after the last study visit:

  • You will have a physical exam.
  • Blood (about 1 tablespoon) will be drawn for routine tests.
  • If the doctor thinks it is needed, photographs will be taken of your skin and any areas affected by the disease.
  • If the doctor thinks it is needed, you will have an x-ray, ultrasound, CT scan, PET/CT scan, and/or a bone scan to check the status of the disease.
  • If the doctor thinks it is needed, you will have an EKG and either an ECHO or MUGA scan.

Follow-up Visits:

You will be called by a member of the study staff every 3 months for up to 1 year after your end-of-treatment visit and asked how you are doing. These calls should last about 2 minutes.

Conditions
Breast Cancer
Being tested
BIBF 1120, Phone Call
Keywords
Breast cancer, Metastatic inflammatory breast cancer, MIBC, HER2-negative, Breast carcinoma, BIBF 1120, Nintedanib, Phone call
Medical subject headings
Breast Neoplasms, Inflammatory Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BIBF 1120Drug

    Also called Nintedanib

    Initial dose is 200 mg twice daily orally for a 28 day cycle.

  • Phone CallBehavioural

    Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. These calls should last about 2 minutes.

Study groups in NCT02389764
Study groupRoleWhat they receive
BIBF 1120ExperimentalInitial dose of BIBF 1120 is 200 mg twice daily orally for a 28 day cycle. Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit.
Receives: Drug: BIBF 1120; Behavioral: Phone Call

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Clinical Benefit Rate (Complete Response [CR], Partial Response [PR] or Stable Disease [SD] Date) of BIBF 1120 (Nintedanib) in Patients With HER2-negative Metastatic Inflammatory Breast Cancer (IBC).

    Clinical benefit defined as participants who achieve CR or PR within 3 months post-treatment, or participants who experience SD for at least three months post-treatment. Clinical benefit rate determined by RECIST 1.1 version." PATHOLOGICAL CR: No evidence of residual invasive tumor, including no residual tumor in the axillary lymph nodes. PR is defined as 30% or greater decrease for a minimum of 4 weeks in the measurable lesion as determined by the product of the perpendicular diameters of the lesion. Every lesion should not regress to qualify as a PR. However, if any lesion progresses or if new lesions appear, the response cannot be classified as a (PR). Minor Response [MR] Decreases in tumor masses insufficient to qualify as a partial remission, i.e. <50%. SD between MR and PD. PD increase in the size by 25% of any measured lesion from baseline. Appearance of new lesions will also constitute increasing disease. Mixed responses will be considered PD.

    Measured: 2 years

Secondary outcomes (1)

  1. Safety Measures of BIBF 1120 in Terms of Type, Frequency and Severity of Adverse Event According to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 in Patients With Metastatic IBC.

    An adverse event (AE) is defined as any untoward medical occurrence, including an exacerbation of a pre-existing condition, in a patient in a clinical investigation who received a pharmaceutical product. The event does not necessarily have to have a causal relationship with this treatment. All adverse events (grade 3 or higher for hematological toxicity, grade 2 or higher for non-hematological toxicity)

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Mar 2015 (estimated)
  2. Study start22 Jun 2015
  3. Primary completion8 Jun 2018
  4. Study completion8 Jun 2019

Why it stopped: Slow Accrual

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02389764
Sponsor's protocol ID
2014-0464
Other IDs
NCI-2015-00506
Status last verified
Jun 2019
First submitted
10 Mar 2015
Last updated
17 Jul 2019
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing BIBF 1120 and Phone Call in people with Breast Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 17 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 17 Jul 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clinical Benefit Rate (Complete Response [CR], Partial Response [PR] or Stable Disease [SD] Date) of BIBF 1120 (Nintedanib) in Patients With HER2-negative Metastatic Inflammatory Breast Cancer (IBC). (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02389764.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2019.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in